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Abstract
Background: Interferon regulatory factor 2 binding protein 2 (IRF2BP2) is a muscle-enriched transcription factor required to
activate vascular endothelial growth factor-A (VEGFA) expression in muscle. IRF2BP2 is found in the nucleus of cardiac and
skeletal muscle cells. During the process of skeletal muscle differentiation, some IRF2BP2 becomes relocated to the
cytoplasm, although the functional significance of this relocation and the mechanisms that control nucleocytoplasmic
localization of IRF2BP2 are not yet known.
Methodology/Principal Findings: Here, by fusing IRF2BP2 to green fluorescent protein and testing a series of deletion and
site-directed mutagenesis constructs, we mapped the nuclear localization signal (NLS) to an evolutionarily conserved
sequence
354ARKRKPSP
361 in IRF2BP2. This sequence corresponds to a classical nuclear localization motif bearing positively
charged arginine and lysine residues. Substitution of arginine and lysine with negatively charged aspartic acid residues
blocked nuclear localization. However, these residues were not sufficient because nuclear targeting of IRF2BP2 also required
phosphorylation of serine 360 (S360). Many large-scale phosphopeptide proteomic studies had reported previously that
serine 360 of IRF2BP2 is phosphorylated in numerous human cell types. Alanine substitution at this site abolished IRF2BP2
nuclear localization in C2C12 myoblasts and CV1 cells. In contrast, substituting serine 360 with aspartic acid forced nuclear
retention and prevented cytoplasmic redistribution in differentiated C2C12 muscle cells. As for the effects of these mutations
on VEGFA promoter activity, the S360A mutation interfered with VEGFA activation, as expected. Surprisingly, the S360D
mutation also interfered with VEGFA activation, suggesting that this mutation, while enforcing nuclear entry, may disrupt an
essential activation function of IRF2BP2.
Conclusions/Significance: Nuclear localization of IRF2BP2 depends on phosphorylation near a conserved NLS. Changes in
phosphorylation status likely control nucleocytoplasmic localization of IRF2BP2 during muscle differentiation.
Citation: Teng ACT, Al-montashiri NAM, Cheng BLM, Lou P, Ozmizrak P, et al. (2011) Identification of a Phosphorylation-Dependent Nuclear Localization Motif in
Interferon Regulatory Factor 2 Binding Protein 2. PLoS ONE 6(8): e24100. doi:10.1371/journal.pone.0024100
Editor: Pierre-Antoine, Universite ´ Paris-Diderot, France
Received April 1, 2011; Accepted July 31, 2011; Published August 26, 2011
Copyright:  2011 Teng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by operating grants from the Canadian Institutes of Health Research (AFRS MOP77682, HHC MOP179197), by a grant in aid
from the Heart and Stroke Foundation of Ontario (HHC NA6301), by an Ontario Graduate Scholarship in Science and Technology (A.T.) and by a scholarship from
Taiba University, Saudi Arabia (N.A.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: astewart@ottawaheart.ca
Introduction
Interferon regulatory factor 2 binding protein 2 (IRF2BP2),
together with the related protein IRF2BP1, were initially
discovered as interacting partners to interferon regulatory factor
2 (IRF2) in a yeast two-hybrid screening assay [1]. A third
homolog of IRF2BP2 called enhanced at puberty 1 (EAP1,
formerly known as C14orf4) is expressed in the mediobasal
hypothalamus and plays a critical function in regulating the female
reproductive neuroendocrine axis [2]. All three are nuclear
proteins.
Structurally, IRF2BP2 is encoded by 2 exons producing 3
alternatively spliced proteins IRF2BP2a of 587, IRF2BP2b of 561
and IRF2BP2c of 163 amino acids depending on the use of
alternative donor (2a and 2b) and acceptor (2c) splice sites.
IRF2BP2a and b isoforms have a Zinc-finger motif at their N-
terminus, missing in the IRF2BP2c isoform, and a C3HC4 RING-
finger motif at their C-terminus. The function of the Zinc-finger
motif appears to enable homo- and hetero-dimerization between
different members of the IRF2BP2 family[3]. The RING-finger
motif from amino acids 456–587 is sufficient to interact with IRF2
[1] and also with nuclear receptor interacting factor 3 (NRIF3) [4].
IRF2BP2 was described as a co-repressor of IRF2, inhibiting the
expression of interferon-responsive genes.
The tumor suppressor p53 binds to the IRF2BP2 promoter and
transactivates its expression in response to actinomycin D
treatments in both cervical carcinoma (HeLa) and osteosarcoma
(U2OS) [5]. Increased endogenous IRF2BP2 protein levels in turn
suppress the induction of apoptosis after genotoxic stress.
Specifically, IRF2BP2 suppresses the transactivation activity of
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24100p53 on both Bax and p21 promoters. Anti-apoptotic activity was
also ascribed to IRF2BP2 due to its modulation of a death domain
in NRIF3 [3–4].
We identified IRF2BP2 as a cofactor of VGLL4 in a yeast two-
hybrid screen [6]. VGLL4 is itself a cofactor of the TEAD
transcription factors [7], that play a critical role controlling gene
expression in skeletal, cardiac and smooth muscle cells [8]. We
showed that transient over-expression of IRF2BP2 and TEAD1
could induce the expression of vascular endothelial growth factor-
A (VEGF-A) in murine C2C12 myoblasts [6]. We also discovered
that IRF2BP2 protein levels increase in response to ischemia in
hindlimb and cardiac muscle. Whereas endogenous IRF2BP2
found in murine C2C12 myoblasts is nuclear, following ischemia,
IRF2BP2 is mostly cytoplasmic. This discrepancy suggests a
potential mechanism for modulating IRF2BP2 translocation
across the nuclear membrane.
Nucleocytoplasmic shuttling is a carefully regulated process
controlling the import and export of both mRNA and proteins [9–
10]. To cross the nuclear membrane, polypeptides use different
mechanisms for translocation; small proteins (,40kDa) diffuse
through the membrane passively while large proteins (.40kDa)
are actively transferred by the nuclear pore complexes (NPCs) on
the nuclear membrane [11]. Nucleocytoplasmic transport encom-
passes many hierarchical steps. To initiate the process, a cargo
protein heterodimerizes with karyopherin via classical nuclear
localization signals (NLS; K-K/R-X-K/R, K= lysine, R=
arginine, X= any amino acids) [9,12]. Next, physical binding of
the guanosine-59-diphosphate (GDP)-bound Ran molecule to the
complex signals to cross the membrane. Once inside the nucleus,
GTP exchange factor (GEF) facilitates the GDP to guanosine-59-
triphosphate (GTP) exchange process, leading to the release of
cargo protein. One of the classical examples of a nuclear shuttled
protein is the T-antigen of SV40 [13].
In this report, we used deletion and site-directed mutagenesis to
localize a conserved functional NLS in IRF2BP2. In addition, we
found that phosphorylation of serine residue 360 (S360) adjacent
to the NLS is also involved in controlling the nuclear entry of the
protein. In silico database mining revealed that this serine residue is
phosphorylated in IRF2BP2 and IRF2BP1, and sequence
comparisons revealed that this motif is conserved in all members
of the IRF2BP2 family of transcription factors. Thus, our study is
the first to reveal a conserved functional domain controlling
nuclear import in IRF2BP2.
Methods and Materials
Plasmid Constructs
Human IRF2BP2a (AY278023) was first amplified by PCR with
the primers 59-GGA TCC GGC TCC TCG GACATG GCC-39
(sense primer, BamHI) and 59-TCT AGA GTC TCT CTC TTT
TTT CAC TTT-39 (antisense primer, XbaI) and was then
subcloned into TOPO vectors (Invitrogen, Carlsbad, CA). To
generate pEGFP-IRF2BP2a, full-length IRF2BP2a was released
from TOPO-IRF2BP2a plasmid by BamHI digestion and then
subcloned in pEGFP-C1 (Clontech, San Jose, CA). A summary of
the GFP-IRF2BP2 fusion constructs is shown in Fig. 6. To
generate the GFP-TEAD4 expression construct, TEAD4 was first
amplified by PCR with the following primers: 59- GAA TTC
TGG AGC CTT GGA GGG CAC GGC - 39 (EcoRI) and 59-
GGA TCC CCG AGT CTC TCA TTC TTT CAC CAG -39
(BamHI) and subcloned into pEGFP-C1 vector between EcoRI
and BamHI sites. For generating mutant constructs, the IRF2BP2
mutants – 355 GAC GAC GAC GAC 358 (aspartic acids), TCT
360 TAT (S360A), and TCT 360 GAT (S360D) - flanked between
the endogenous PstI and NcoI in IRF2BP2 were ordered from
Integrated DNA Technologies (San Diego, CA) as pIDTSMART-
IRF2BP2 and were subcloned in pEGFP-IRF2BP2a (Cloning
details will be provided upon inquiry). Similarly, a pEGFP-
IRF2BP2b construct was generated by swapping a PstI/NcoI
fragment of IRF2BP2b into the pEGFP-IRF2BP2a clone. All
plasmid constructs were purified by CsCl-banding and their
reading frames were verified by sequencing. DsRed-Rab11 WT
(Addgene plasmid 12679) and RFP-LAMP1 (Addgene plasmid
1817) expression vectors were obtained from Addgene (Cam-
bridge, MA). Expression vectors for wild type IRF2BP2, S360A
and S360D mutants were generated by subcloning a full-length
EcoR1 fragment from pEGFP-IRF2BP2 into the pXJ40-CMVHA
vector. The mouse VEGFA promoter construct was described
previously [6].
Tissue culture, transient transfections and luciferase
assays
C2C12 myoblasts and African green monkey kidney (CV1) cells
were obtained from American Type Culture Collection (Rockville,
MD). Cells were maintained in high glucose DMEM with 20%
FBS (or 10% FBS for CV1), 100 U/ml penicillin, 100 ug/ml
streptomycin. Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and
GenJet Reagent (Cat # SL100489- C2C12, SignaGen Laborato-
ries, Ijamsville, MD) were used to transfect CV1 and C2C12
myoblasts, respectively, according to the manufacturer’s instruc-
tions. Luciferase assays were conducted as described previously [6]
and luciferase activities were expressed as mean fold 6 SEM
relative to the empty pXJ40CMV vector. Differences between fold
luciferase activities were compared by Student’s t-test and
considered significant at p,0.05.
Protein kinase inhibitors
The protein kinase A (PKA) inhibitor H89 (working concen-
tration: 20 mM, Cat. #: B1427), the inhibitor of phosphoinositide
3-kinases LY294002 (10 mM, L9908), and the MEK1/MEK2
inhibitor U0126 (10 mM, #U120) were from Sigma-Aldrich
(Oakville, ON., Canada). The calcium/calmodulin-dependent
protein kinase II (CaMKII) inhibitor CK-59 (100 mM, #208922)
and the ribosomal S6 kinase (RSK) inhibitor SL0101 (10 mM,
#559285) were from Calbiochem (Gibbstown, NJ). The cyclin
dependent kinase inhibitor olomoucine (10 mM, #V2372) was
from Promega (Madison, WI).
Immunofluorescence
The rabbit polyclonal anti-IRF2BP2 antibody was described
previously [6]. Rabbit polyclonal PRDX3 antibody (ab50300) was
purchased from Abcam Inc., (Cambridge, MA). Alexa488-
conjugated goat anti-mouse and Alexa594-conjugated goat anti-
rabbit antibodies were from Santa Cruz Biotechnology Inc.,
(Santa Cruz, CA). 48-hours post transfection, cells were washed
twice with 1x phosphate-buffered saline (PBS; 3.2 mM Na2HPO4,
0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, pH 7.4), fixed in
ice-cold methanol at 220uC for 10 minutes, washed thrice with 1x
PBS, permeabilized by 0.5% Triton-X 100, and washed thrice
with 1x PBS. Cells were then counter-stained with 49,6-diamidino-
2-pheylindole (DAPI, Sigma), mounted on glass slides, and
visualized on a Zeiss M1 microscope.
Results
IRF2BP2b is a nuclear protein in mouse C2C12 myoblasts that
becomes redistributed to the cytoplasm during muscle differenti-
ation [6]. The nuclear targeting sequence has not been identified
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IRF2BP2 fusion constructs to enable the identification of
sequences necessary and sufficient for this process. The GFP
protein is localized to the cytoplasm of C2C12 myoblasts whereas a
control construct fusing GFP to the TEAD4 transcription factor is
localized to the nucleus of C2C12 myoblasts (Fig. 1A). The GFP-
IRF2BP2a and GFP-IRF2BP2b fusion proteins were detected in
the nucleus of C2C12 myoblasts (Fig. 1C,D). Since the both
isoforms localized to the nucleus, we chose IRF2BP2a for
subsequent studies.
Using convenient restriction sites, we found that the N-terminal
sequence of IRF2BP2 encoded by exon 1 (amino acids 1-333) was
not imported into the nucleus, whereas a fragment encoded largely
by exon 2 (amino acids 333–587) was localized in the nucleus
(Fig. 2). A fragment containing amino acids 101–422 was also
localized in the nucleus, identifying a nuclear targeting sequence
between amino acids 333 and 422. The GFP-IRF2BP2(Ex1)
fusion protein was found in cytoplasmic speckles (Fig. 2B,C). To
determine the cellular localization of this fragment, we tested for
colocalization with a mitochondrial protein (peroxiredoxin 3,
PRDX3), a lysosome associated membrane protein (LAMP) and a
Golgi body targeted protein Ras-related protein 11 (Rab11) using
specific antibodies. We found that the N-terminal fragment of
IRF2BP2 is targeted to the lysosome, and is likely degraded
(Fig. 2C).
Given that the C-terminal fragment of IRF2BP2 is targeted to
the nucleus, we sought to identify the minimal nuclear localization
sequences (NLS) within this fragment. Bioinformatic analyses
(Fig. 3A) suggested two putative NLS in conserved regions of
IRF2BP2, one at the N-terminus of exon 2 encoded sequence we
called Ex2N,
357ARKRKP
364 and the other and the C-terminus
we called Ex2C,
579KVKKERD
587. To evaluate whether these
sites are functional, the second exon was further divided into three
parts, namely 333-422, 422–587, and 575–587, fused with GFP,
and then transiently overexpressed in C2C12 myoblasts. Here, the
333–422 fragment was found in the nucleus (Fig. 3B), but the C-
terminal Ex2C 575–587 fragment or the 422–587 fragment did
not. Thus, the Ex2C sequence is not an NLS, nor is a cryptic NLS
present in the sequences from amino acids 422 to 587. To
authenticate the NLS at Ex.2N, positively charged amino acids
were replaced by negatively charged aspartic acids (DDDD) using
site-directed mutagenesis (Fig. 3C). When expressed in C2C12
Figure 1. Green fluorescent protein (GFP) full-length IRF2BP2
fusion constructs are targeted to the nucleus. A. GFP alone was
localized in the cytoplasm of C2C12 myosblasts. B. A GFP fusion
construct with the nuclear-targeted transcription factor TEAD4 was
nuclear localized in C2C12 myoblasts. C. GFP-IRF2BP2a was localized to
the nucleus of C2C12 myoblasts. D. GFP-IRF2BP2b was also nuclear in
C2C12 myoblasts. Nuclei were revealed by DAPI in blue. Scale bar,
50 mm.
doi:10.1371/journal.pone.0024100.g001
Figure 2. Nuclear localization signal is contained within the C-
terminal half of IRF2BP2. A. Diagram of GFP fusion IRF2BP2 deletion
contructs used to localize the NLS. B. The N-terminal fragment, GFP-
IRF2BP2(Ex1) is cytoplasmic, whereas the middle, GFP-IRF2BP2(MscI),
and C-terminal, GFP-IRF2BP2(Ex2P), fragments are nuclear in C2C12
myoblasts. C. The N-terminal fragment is targeted to the lysosome in
C2C12 myoblasts. Mitochondrial-specific peroxiredoxin 3 (PRDX3) and
Golgi body-sepcific Ras-related protein 11 (Rab11) did not, whereas the
lysosome-associated membrane protein (LAMP) did co-localize with
GFP-IRF2BP2(Ex1). Scale bars, 50 mm.
doi:10.1371/journal.pone.0024100.g002
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confirming that the Ex2N NLS in IRF2BP2 is functional (Fig. 3C).
A survey of phosphopeptide databases generated from large
scale proteomic studies that employed mass spectrometry revealed
that IRF2BP2 is phosphorylated at serine 360 (S360), two amino
acids downstream of the newly identified Ex2N NLS, in many
human cell types (Table 1). To test whether phosphorylation of
S360 affects nuclear import of IRF2BP2, we mutagenized the
serine to either an alanine (S360A) that cannot be phosphorylated
or to an aspartic acid (S360D), that carries a negative charge and
mimics phosphorylation. The GFP-IRF2BP2 S360A mutant was
localized in the cytoplasm of C2C12 myoblasts. To rule out that the
Figure 3. Identification of the NLS within the C-terminal half of IRF2BP2. A. Two putative NLS sequences were identified in conserved
regions of IRF2BP2. Core arginine (R) and lysine (K) sequences are highlighted in yellow. B. GFP fusion constructs with the amino acid positions
indicated were tested in C2C12 myoblasts to reveal that the sequence between amino acid 333 and 422 contains the functional NLS of IRF2BP2. C.
Site-directed mutagenesis converting the R and K to aspartic acid (D) residues prevented nuclear localization. Scale bar, 50 mm.
doi:10.1371/journal.pone.0024100.g003
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B (10 nM) was used to block CRM1-dependent nuclear export,
but it did not cause nuclear retention of the GFP-IRF2BP2 S360A
mutant (Fig. S1). Thus, cytosolic localization of the GFP-IRF2BP2
S360A mutant likely results from failure to import rather than a
CRM1-dependent nuclear export. In contrast, the GFP-IRF2BP2
S360D mutant was located in the nucleus (Fig. 4A). During
skeletal muscle differentiation of C2C12 cells, we reported
previously that IRF2BP2 is partially relocated to the cytoplasm
[6]. Thus, we asked whether the S360D mutant would enforce
nuclear retention of IRF2BP2 in C2C12 cells 72 hours after the
induction of muscle differentiation. Both the endogenous
IRF2BP2 and the GFP fusion protein bearing full-length wild
type IRF2BP2 were localized in both the cytoplasm and nucleus,
whereas the S360D mutant was exclusively nuclear (Fig. 4B).
When co-expressed with the transcription factor TEAD1, we
reported previously that IRF2BP2 strongly co-activates a mouse
VEGFA promoter in African green monkey kidney CV1 cells,
where endogenous IRF2BP2 levels are low[6]. We also observed
nuclear exclusion of the S360A mutant of IRF2BP2 and nuclear
retention of the S360D mutant in CV1 cells (Fig. 5A). We next
tested whether nuclear exclusion of IRF2BP2 would block and
whether forced nuclear retention of IRF2BP2 would enhance
mouse VEGF promoter activity in the presence of TEAD1.
Compared to wildtype IRF2BP2 co-expressed with TEAD1, not
only did the alanine mutant fail to co-activate the VEGFA
promoter, as expected, but surprisingly the aspartic acid mutant
also failed to co-activate the VEGFA promoter in CV1 cells
(Fig. 5B). We confirmed that TEAD1 and the wild type and the
mutant IRF2BP2 proteins were expressed at comparable levels
and were of the expected size by immunoblot analysis of
transfected CV1 cells (Fig. 5C). Thus, although the aspartic acid
substitution of serine 360 forces nuclear retention of IRF1BP2, it
also appears to disrupt the co-activation function of IRF2BP2.
Currently, we do not know which kinase is responsible for the
phosphorylation of S360. From a list of candidate kinases includes
protein kinase A (PKA, consensus sequence R-R/K-X-S/T),
kinase B (PKB), kinase C (PKC), kinase G (PKG), ribosomal S6
kinase (RSK), extracellular signal-regulated kianses 1/2 (ERK1/2,
X-X-S/T-P), calmodulin-dependent protein kinase II (CaMKII,
R-X-X-S/T), and Cdc2 (S/T-P-X-R/L), we tested various
inhibitors against these kinases to determine whether they would
cause cytoplasmic retention of IRF2BP2. However, in no case was
IRF2BP2 excluded from the nucleus of C2C12 myoblasts 24 hours
post-treatment (Fig. S2).
Table 1. Serine 360 of IRF2BP2 is phosphorylated in multiple
human cell types.
Human Cell line/tissues Identified peptides Reference
HeLa (cervical carcinoma) RKPpSPEPEGEVGPPK [26]
NCI-H1299 (non-small cell
lung cancer)
KPpSPEPEGEVGPPK [28]
HeLa (cervical carcinoma) KRKRpSPEPEGEVGPPK [29]
Embryonic stem cells (male) KPpSPEPEGEVGPPK [30]
MV4-11 (myeloid) RKPpSPEPEGEVGPPK [31]
Jurkat (T lymphocytes) VARTARKRKPpSPEPEGEVGPP [27]
Hepatocellular carcinoma RKPpSPEPEGEVGPPK [32]
Leukocyte-blood RKPpSPEPEGEVGPPK [33]
Fragments analyzed by mass spectrometry were identified by mining online
datasets.
doi:10.1371/journal.pone.0024100.t001
Figure 4. Phosphorylation of serine 360 controls nuclear localization of IRF2BP2. A. Site-directed mutagenesis of serine 360 to alanine
(S360A) blocked nuclear localization of IRF2BP2 whereas aspartic acid substitution (S360D) did not differ from wild type and was nuclear localized in
C2C12 myoblasts. B. After 72 hours in differentiation medium, the endogenous IRF2BP2 (revealed with IRF2BP2 antibody), as well as GFP-IRF2BP2 (wild
type, green), are localized in both the cytoplasm and nucleus of C2C12 myotubes. The S360D mutant was exclusively found in the nucleus in C2C12
myotubes.
doi:10.1371/journal.pone.0024100.g004
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single phosphorylation-modulated NLS in IRF2BP2. This se-
quence is conserved across the different paralogous homologs in
both humans and zebrafish (Fig. 6B).
Discussion
Nuclear import of IRF2BP2 depends not only on a classical
nuclear localization sequence, but also on phosphorylation of
serine 360. Although our studies have not identified the protein
kinase responsible for this phosphorylation event, the cytoplasmic
localization of IRF2BP2 in differentiating skeletal muscle cells
suggests that this protein kinase might become down-regulated or
inactivated. Preventing nuclear entry of IRF2BP2 by mutating
S360A was sufficient to render the protein inactive to regulate
VEGFA promoter activity. Surprisingly, forced nuclear localiza-
tion did not make IRF2BP2 a better transactivator of VEGFA.
This result indicates that nuclear localization is not sufficient to
ensure transcriptional activity of IRF2BP2 and that the S360D
mutation might affect the interaction of IRF2BP2 with a putative
transcription cofactor or affect a transactivation function of
IRF2BP2.
Nuclear trafficking is a fundamental and essential mechanism to
modulate import and export of RNA and proteins across the
nuclear membranes within eukaryotes. This process depends
heavily on thousands of protein complexes on the nuclear
envelope and the import/export signals on cargo molecules. The
classic NLS, composed of a cluster of arginine and lysine residues,
has been extensively studied. X-ray crystallography shows that the
positive charges from lysine and arginine enhance the binding
affinity to negatively charged armadillo pockets of karyopherin-a
[14]. Karyopherin-a serves as an adaptor between a cargo protein
and karyopherin-b. Nevertheless, other studies have shown that
karyopherin-a could directly interact with a cargo protein [15].
Our study showed that one of two putative sequences was a
functional NLS required for IRF2BP2 for nuclear entry.
Post-translational modifications are important for modulating
protein structures or functions for downstream actions in response
to environmental cues. One of frequently encountered examples
includes phosphorylation [17–20]. Database mining revealed that
IRF2BP2 is phosphorylated at several serine residues in addition
to serine 360 (data not shown). Serine 360 is located two amino
acids downstream from the NLS (Fig. 6B) and our site-directed
mutagenesis studies are consistent with phosphorylation at this site
being necessary for nuclear entry, because blocking this process by
mutagenesis led to perinuclear accumulation of the mutant protein
(S360A), even in the presence of the NLS. A possible explanation
is that phosphorylation of the serine residue is likely to alter
IRF2BP2 protein structure, strengthening the stability of
IRF2BP2-karyopherin complexes for crossing the nuclear mem-
brane. Many examples for phosphorylation-dependent nuclear
entry exist in eukaryotes, including import of extracellular signal-
regulated kinase-1/2 (ERK1/2) [21], histone deacetylase 4
(HDAC4) [22], forkhead box M1 (FOXM1) [23], and adenoma-
tous polyposis cell (APC) protein [24]. However, we were not able
to identify the kinase that phosphorylates S360. This might be due
Figure 5. Despite forced nuclear retention the S360D mutant did not produce a dominantly active form of IRF2BP2. A. The S360A
mutant of IRF2BP2 was cytoplasmic and the S360D mutant was nuclear in CV1 cells. Scale bar, 50 mm. B. The wild type IRF2BP2 augmented TEAD1-
dependent activation of the mouse VEGFA promoter in CV1 cells (asterisk, p,0.05). The S360A and the S360D both failed to co-activate VEGFA when
co-expressed with TEAD1. N=3 experiments. C. Immunoblot analysis of protein lysates from transfected CV1 cells revealed similar levels of wild type
and mutant IRF2BP2 proteins.
doi:10.1371/journal.pone.0024100.g005
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low-density lipoprotein (LDL)-receptor-related protein 6 (LRP6)
can be phosphorylated by both glycogen synthase kinase 3 (GSK3)
and casein kinase I (CKI) [25].
The discovery of a single classical NLS in IRF2BP2 may help to
predict the NLS in both IRF2BP1 and EAP1. The results show a
striking similarity in sequence conservation, with both paralogs
having a conserved NLS and a conserved phosphorylation target
in an adjacent serine (Fig. 6B). Mass-spectrometry confirms that
both S384 of IRF2BP1 [26] and S547 of EAP1 [27] are
phosphorylated in vivo. It remains to be formally proven whether
both NLS signals and the serine residues provide similar functions
as those observed in this study for IRF2BP2. It is worth noting that
the locations of these sequences are not in currently known
functional domains. This is consistent with previous studies
showing that an NLS is most often away from other functional
motifs to avoid interference. Our study provides important insight
into the position of the nuclear targeting signals in the IRF2BP2
family of transcription factors.
Supporting Information
Figure S1 Blocking CRM1 nuclear export did not cause
retention of the S360A mutant of IRF2BP2.C 2C12
myoblasts transfected with GFP-IRF2BP2 (S360A) were treated
with vehicle (1 ml 70% methanol in 1 ml medium, Control) or
leptomycin B (10 nM, LMB). Scale bar, 10 mm.
(TIF)
Figure S2 Various protein kinase inhibitors failed to
block nuclear import of endogenous IRF2BP2. C2C12
myoblasts were treated with vehicle (DMSO) or inhibitors of
protein kinases for 24 hours. Scale bar, 50 mm. See Methods and
Materials for descriptions and concentrations of protein kinase
inhibitors.
(TIF)
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